Pathogen-based target attainment of optimized continuous infusion dosing regimens of piperacillin-tazobactam and meropenem in surgical ICU patients: a prospective single center observational study

[1] De Bus L(2018)A complete and multifaceted overview of antibiotic use and infection diagnosis in the intensive care unit: results from a prospective four-year registration Crit Care 22 241-1487

[2] Gadeyne B(2020)Prevalence and outcomes of infection among patients in intensive care units in 2017 JAMA 323 1478-1083

[3] Steen J(2014)DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58 1072-1153

[4] Boelens J(2020)Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper Intensive Care Med 46 1127-321

[5] Claeys G(2022)Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial Intensive Care Med 48 311-1860

[6] Benoit D(2022)Beta-lactam antibiotic therapeutic drug monitoring in critically Ill patients: a systematic review and meta-analysis Clin Infect Dis 75 1848-94

[7] Vincent JL(2015)Ultrafast quantification of β-lactam antibiotics in human plasma using UPLC-MS/MS J Chromatogr, B: Anal Technol Biomed Life Sci 978–979 89-3775

[8] Sakr Y(1997)The pharmacology of meropenem, a new carbapenem antibiotic Clin Infect Dis 36 3765-150

[9] Singer M(2012)COSARA: integrated service platform for infection surveillance and antibiotic management in the ICU J Med Syst 3 1-138

[10] Martin-Loeches I(2013)Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease Kidney Int Suppl 2 1-1121

[1] De Bus L(2018)A complete and multifaceted overview of antibiotic use and infection diagnosis in the intensive care unit: results from a prospective four-year registration Crit Care 22 241-1487

[2] Gadeyne B(2020)Prevalence and outcomes of infection among patients in intensive care units in 2017 JAMA 323 1478-1083

[3] Steen J(2014)DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58 1072-1153

[4] Boelens J(2020)Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper Intensive Care Med 46 1127-321

[5] Claeys G(2022)Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial Intensive Care Med 48 311-1860

[6] Benoit D(2022)Beta-lactam antibiotic therapeutic drug monitoring in critically Ill patients: a systematic review and meta-analysis Clin Infect Dis 75 1848-94

[7] Vincent JL(2015)Ultrafast quantification of β-lactam antibiotics in human plasma using UPLC-MS/MS J Chromatogr, B: Anal Technol Biomed Life Sci 978–979 89-3775

[8] Sakr Y(1997)The pharmacology of meropenem, a new carbapenem antibiotic Clin Infect Dis 36 3765-150

[9] Singer M(2012)COSARA: integrated service platform for infection surveillance and antibiotic management in the ICU J Med Syst 3 1-138

[10] Martin-Loeches I(2013)Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease Kidney Int Suppl 2 1-1121